IBERSOL SGPS SA (IBS.LS) Fundamental Analysis & Valuation

ELI:IBS • PTIBS0AM0008

Current stock price

11.5 EUR
-0.28 (-2.38%)
Last:

This IBS.LS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. IBS.LS Profitability Analysis

1.1 Basic Checks

  • In the past year IBS was profitable.
  • IBS had a positive operating cash flow in the past year.
  • Of the past 5 years IBS 4 years were profitable.
  • In the past 5 years IBS always reported a positive cash flow from operatings.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • IBS has a Return On Assets (1.91%) which is comparable to the rest of the industry.
  • IBS has a Return On Equity (4.21%) which is comparable to the rest of the industry.
  • IBS's Return On Invested Capital of 4.53% is in line compared to the rest of the industry. IBS outperforms 46.43% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IBS is significantly below the industry average of 12.48%.
  • The 3 year average ROIC (3.32%) for IBS is below the current ROIC(4.53%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROIC 4.53%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.56%, IBS is in line with its industry, outperforming 44.64% of the companies in the same industry.
  • IBS's Profit Margin has declined in the last couple of years.
  • IBS's Operating Margin of 5.83% is in line compared to the rest of the industry. IBS outperforms 44.64% of its industry peers.
  • In the last couple of years the Operating Margin of IBS has declined.
  • IBS has a Gross Margin (52.62%) which is in line with its industry peers.
  • IBS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. IBS.LS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IBS is destroying value.
  • IBS has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IBS has been increased compared to 5 years ago.
  • IBS has a worse debt/assets ratio than last year.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • IBS has an Altman-Z score of 2.20. This is not the best score and indicates that IBS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.20, IBS is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
  • The Debt to FCF ratio of IBS is 3.47, which is a good value as it means it would take IBS, 3.47 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 3.47, IBS is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • A Debt/Equity ratio of 0.66 indicates that IBS is somewhat dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.66, IBS is doing good in the industry, outperforming 67.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Altman-Z 2.2
ROIC/WACC0.72
WACC6.32%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.02 indicates that IBS should not have too much problems paying its short term obligations.
  • The Current ratio of IBS (1.02) is better than 64.29% of its industry peers.
  • A Quick Ratio of 0.92 indicates that IBS may have some problems paying its short term obligations.
  • IBS has a Quick ratio (0.92) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.92
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IBS.LS Growth Analysis

3.1 Past

  • IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.66%.
  • Measured over the past years, IBS shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.23% on average per year.
  • Looking at the last year, IBS shows a quite strong growth in Revenue. The Revenue has grown by 15.02% in the last year.
  • Measured over the past years, IBS shows a decrease in Revenue. The Revenue has been decreasing by -0.46% on average per year.
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%

3.2 Future

  • Based on estimates for the next years, IBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.57% on average per year.
  • IBS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.42% yearly.
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue Next Year15.12%
Revenue Next 2Y10.16%
Revenue Next 3Y8.33%
Revenue Next 5Y7.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. IBS.LS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 33.82, which means the current valuation is very expensive for IBS.
  • Compared to the rest of the industry, the Price/Earnings ratio of IBS is on the same level as its industry peers.
  • IBS's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.54.
  • A Price/Forward Earnings ratio of 36.34 indicates a quite expensive valuation of IBS.
  • The rest of the industry has a similar Price/Forward Earnings ratio as IBS.
  • The average S&P500 Price/Forward Earnings ratio is at 21.68. IBS is valued rather expensively when compared to this.
Industry RankSector Rank
PE 33.82
Fwd PE 36.34
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, IBS is valued cheaply inside the industry as 82.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 5.68
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.66%
EPS Next 3Y2.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. IBS.LS Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 5.93%, IBS is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.47, IBS pays a better dividend. On top of this IBS pays more dividend than 94.64% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, IBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.93%

5.2 History

  • On average, the dividend of IBS grows each year by 48.65%, which is quite nice.
Dividend Growth(5Y)48.65%
Div Incr Years1
Div Non Decr Years1
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • IBS pays out 213.50% of its income as dividend. This is not a sustainable payout ratio.
  • IBS's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP213.5%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IBS.LS Fundamentals: All Metrics, Ratios and Statistics

IBERSOL SGPS SA

ELI:IBS (4/29/2026, 7:00:00 PM)

11.5

-0.28 (-2.38%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Industry Strength27.7
Industry Growth38
Earnings (Last)11-27
Earnings (Next)04-27
Inst Owners21.86%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap470.35M
Revenue(TTM)522.73M
Net Income(TTM)13.37M
Analysts83.33
Price Target11.92 (3.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.93%
Yearly Dividend0.49
Dividend Growth(5Y)48.65%
DP213.5%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.41%
Max Revenue beat(2)-0.81%
Revenue beat(4)2
Avg Revenue beat(4)4.87%
Min Revenue beat(4)-3.41%
Max Revenue beat(4)12.41%
Revenue beat(8)6
Avg Revenue beat(8)5.92%
Revenue beat(12)8
Avg Revenue beat(12)5.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.71%
Valuation
Industry RankSector Rank
PE 33.82
Fwd PE 36.34
P/S 0.9
P/FCF 5.68
P/OCF 3.66
P/B 1.48
P/tB 2.15
EV/EBITDA N/A
EPS(TTM)0.34
EY2.96%
EPS(NY)0.32
Fwd EY2.75%
FCF(TTM)2.02
FCFY17.6%
OCF(TTM)3.15
OCFY27.35%
SpS12.78
BVpS7.76
TBVpS5.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.70396 (-33.01%)
Profitability
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROCE 5.74%
ROIC 4.53%
ROICexc 5.96%
ROICexgc 7.87%
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
FCFM 15.84%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
ROICexc(3y)5.24%
ROICexc(5y)N/A
ROICexgc(3y)7.05%
ROICexgc(5y)N/A
ROCE(3y)4.21%
ROCE(5y)N/A
ROICexgc growth 3Y-24.94%
ROICexgc growth 5Y-3.32%
ROICexc growth 3Y-22.88%
ROICexc growth 5Y-3.24%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
F-Score7
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.77%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 619.36%
Current Ratio 1.02
Quick Ratio 0.92
Altman-Z 2.2
F-Score7
WACC6.32%
ROIC/WACC0.72
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)9.76%
Cap/Sales(5y)11.65%
Profit Quality(3y)200.89%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%
Revenue Next Year15.12%
Revenue Next 2Y10.16%
Revenue Next 3Y8.33%
Revenue Next 5Y7.42%
EBIT growth 1Y34.45%
EBIT growth 3Y-20.54%
EBIT growth 5Y-7.19%
EBIT Next Year476.27%
EBIT Next 3Y85.5%
EBIT Next 5Y61.42%
FCF growth 1Y88.1%
FCF growth 3Y-0.14%
FCF growth 5Y-9.32%
OCF growth 1Y61.81%
OCF growth 3Y1.82%
OCF growth 5Y-6.35%

IBERSOL SGPS SA / IBS.LS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IBERSOL SGPS SA (IBS.LS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IBS.LS.


Can you provide the valuation status for IBERSOL SGPS SA?

ChartMill assigns a valuation rating of 2 / 10 to IBERSOL SGPS SA (IBS.LS). This can be considered as Overvalued.


What is the profitability of IBS stock?

IBERSOL SGPS SA (IBS.LS) has a profitability rating of 4 / 10.


Can you provide the financial health for IBS stock?

The financial health rating of IBERSOL SGPS SA (IBS.LS) is 5 / 10.


What is the expected EPS growth for IBERSOL SGPS SA (IBS.LS) stock?

The Earnings per Share (EPS) of IBERSOL SGPS SA (IBS.LS) is expected to decline by -38.06% in the next year.